Generation Investment Management LLP Has $166.36 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Generation Investment Management LLP reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 54.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 260,394 shares of the company’s stock after selling 306,928 shares during the period. IDEXX Laboratories makes up 1.1% of Generation Investment Management LLP’s holdings, making the stock its 22nd biggest holding. Generation Investment Management LLP’s holdings in IDEXX Laboratories were worth $166,363,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 0.9% in the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after acquiring an additional 86,040 shares during the last quarter. Geode Capital Management LLC increased its position in IDEXX Laboratories by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after purchasing an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp increased its position in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after purchasing an additional 605,290 shares in the last quarter. Principal Financial Group Inc. lifted its stake in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares in the company, valued at $407,345.76. This represents a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 18,180 shares of company stock valued at $11,626,996 over the last quarter. Insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research analyst reports. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Piper Sandler dropped their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. UBS Group cut their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Finally, Morgan Stanley upped their price objective on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Trading Down 2.0%

NASDAQ IDXX opened at $623.13 on Tuesday. The firm has a market capitalization of $49.76 billion, a PE ratio of 47.68, a price-to-earnings-growth ratio of 3.87 and a beta of 1.67. The business’s 50-day moving average price is $676.19 and its two-hundred day moving average price is $669.13. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the business earned $2.53 earnings per share. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.